MBAL Med Line Clinic AD

The clinic is investigating ulcerative colitis with an innovative oral formulation aimed at achieving clinical remission and improving patient quality of life.

• Induction of remission in mild to moderate ulcerative colitis
• Evaluation of endoscopic and symptomatic outcomes
• Safety and tolerability of new oral therapy

MBAL Med Line Clinic AD is committed to advancing digestive health through patient‑centered trials.

Researchers are addressing obesity and type 2 diabetes by testing novel combinations that enhance weight loss and glycaemic control, while also monitoring cardiovascular risk.

• Evaluating weight‑loss efficacy of emerging agents
• Improving glycaemic outcomes in patients inadequately managed with current therapy
• Assessing cardiovascular safety in metabolic disease populations

Located in Plovdiv, the department leverages multidisciplinary expertise to address metabolic challenges.

The program examines chronic kidney disease, cardiovascular disease and diabetic retinopathy to determine how new treatments can protect organ function and reduce long‑term complications.

• Slowing renal function decline with combination therapy
• Investigating long‑term impact on diabetic eye disease
• Confirming cardiovascular safety of novel agents in at‑risk patients

The Department of Endocrinology and Metabolic Diseases at MBAL Med Line Clinic AD conducts these studies to translate metabolic research into clinical benefit.